Paul Tudor Jones’s Cytek Biosciences CTKB Stock Holding History

Paul Tudor Jones’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.71M	Buy	837,913 +517,198	+161%	+$2.21M	0.01%	1492
2026 Q1	$1.4M	Buy	+320,715	New	+$1.51M	﹤0.01%	2125
2025 Q4	–	Sell	-249,812	Closed	-$867K	–	3576
2025 Q3	$867K	Buy	+249,812	New	+$938K	﹤0.01%	2374
2023 Q2	–	Sell	-123,997	Closed	-$1.14M	–	2515
2023 Q1	$1.14M	Buy	+123,997	New	+$1.33M	0.02%	1118

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Paul Tudor Jones's CTKB Position: Q2 2026 in Review

Paul Tudor Jones increased its Cytek Biosciences (CTKB) stake by 161% in Q2 2026, buying an estimated $2.21M and bringing the position to 837,913 shares worth $3.71M. The position accounts for 0.01% of the portfolio, ranked #1492.

Paul Tudor Jones first reported a position in CTKB in Q1 2023 and has held it in 4 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Paul Tudor Jones held 837,913 shares of Cytek Biosciences worth $3.71M as of Q2 2026.
Paul Tudor Jones bought 517,198 Cytek Biosciences shares in Q2 2026, an estimated $2.21M.
Cytek Biosciences made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1492 holding.
Paul Tudor Jones first reported a position in Cytek Biosciences in Q1 2023 and has held it in 4 quarters since.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.